Strata Critical Medical Reports Strong Q3 2026 Growth Driven by Clinical Segment and Acquisitions
Strata Critical Medical (SRTA) reported significant third-quarter 2026 results, with total revenue reaching $74.1 million, a 50.3% increase year-over-year. This growth was primarily fueled by strategic acquisitions and organic expansion within the clinical services segment, which saw revenue rise to $29.2 million. While logistics revenue experienced a slight decline due to industry-wide reductions in average trip distances, the company's overall profitability improved significantly. Adjusted EBITDA rose to $9.6 million, up from $4.2 million in the prior year period, resulting in an expanded margin of 13%. The company also demonstrated strong cash flow management with $8.6 million in free cash flow and announced a new $20 million share repurchase authorization. Looking ahead, management provided optimistic full-year guidance and set ambitious 2027 targets for both organic and total adjusted EBITDA growth.
Tickers: $JOBY
Topics: adjusted EBITDA clinical services logistics revenue margin expansion revenue growth